Delayed vs initial cytomegalovirus prophylaxis after kidney transplantation

Area of Science:

• Transplant medicine
• Infectious disease management
• Pharmacoeconomics

Background:

• Cytomegalovirus (CMV) prophylaxis is standard post-transplant care.
• Current guidelines recommend initiation within 10 days of transplant.
• A cost-saving initiative explored delaying prophylaxis from day 0 to day 7 or discharge.

Purpose of the Study:

• To evaluate the clinical outcomes of early versus delayed CMV prophylaxis.
• To assess the impact of delayed prophylaxis on CMV infection and disease incidence.
• To determine the cost-effectiveness of delayed CMV prophylaxis in kidney and kidney/pancreas transplant recipients.

Main Methods:

• Retrospective study of 173 kidney and kidney/pancreas transplant recipients (June 2014-January 2017).
• Comparison of early (<72 hours) versus delayed (>72 hours) CMV prophylaxis initiation.
• Primary endpoint: CMV infection incidence within 1 year; Secondary endpoints: CMV disease, testing, and valganciclovir costs.

Main Results:

• No significant difference in CMV infection rates between early (61%) and delayed (54%) prophylaxis groups (P=0.5).
• Excluding low-level DNAemia, infection rates were 30% (early) vs 22% (delayed) (P=0.4).
• Delayed prophylaxis resulted in median cost savings of $497.00 per patient (P<0.05).

Conclusions:

• Delaying CMV prophylaxis initiation beyond 72 hours is safe and does not negatively impact clinical outcomes.
• Delayed prophylaxis offers significant cost savings during the index hospitalization.
• This strategy supports cost-containment efforts in transplant centers without compromising patient care.